Zydus Cadila's Pegylated Interferon alpha-2b drug, 'Virafin', has received Emergency Use Approval from DCGI, the Drugs Controller General of India. Pharma giant Zydus Cadila says its anti-viral drug Virafin can not only reduce the need for medical oxygen but also improve recovery time among Covid-19 patients. Earlier launched as PegiHep, the drug was being used to treat Hepatitis C. A …
Drug firm Zydus Cadila on Monday said it has sought approval from the domestic drug regulator Drugs Controller General of India for additional indication of its hepatitis drug Pegylated Interferon Alpha-2b for treating COVID-19. Phase-III clinical trials with Pegylated Interferon Alpha 2b, which company sells under the brand name 'PegiHep' has shown promising results in treating COVID-19, Zydus Cadila said …
Zydus Cadila on Monday said it had sought approval from the Drugs Controller General of India for use of its viral hepatitis drug in treating Covid-19 after its Phase 3 clinical trials showed promising results. The drug reduced the duration for supplemental oxygen to 56 hours from 84 hours in moderate Covid-19 patients, Zydus Cadila said in a statement. “With …
)
